The data published in NEJM highlight the positive Phase 3 VALIANT results at Week 26, which were consistent across adolescent and adult patients with C3G and primary IC-MPGN, including patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback